Cargando…

Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes

BACKGROUND: The coronavirus disease 2019 (COVID-19) has spread rapidly around the world. In addition to common respiratory symptoms such as cough and fever, some patients also have cardiac injury, however, the mechanism of cardiac injury is not clear. In this study, we analyzed the RNA expression at...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Chen, Tan, Zhou, Yafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781406/
https://www.ncbi.nlm.nih.gov/pubmed/33397514
http://dx.doi.org/10.1186/s41065-020-00168-4
_version_ 1783631672128831488
author Yang, Jing
Chen, Tan
Zhou, Yafeng
author_facet Yang, Jing
Chen, Tan
Zhou, Yafeng
author_sort Yang, Jing
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID-19) has spread rapidly around the world. In addition to common respiratory symptoms such as cough and fever, some patients also have cardiac injury, however, the mechanism of cardiac injury is not clear. In this study, we analyzed the RNA expression atlases of angiotensin-converting enzyme 2(ACE2), cathepsin B (CTSB) and cathepsin L (CTSL) in the human embryonic heart at single-cell resolution. RESULTS: The results showed that ACE2 was preferentially enriched in cardiomyocytes. Interestingly, serine protease transmembrane serine protease 2 (TMPRSS2) had less expression in cardiomyocytes, but CTSB and CTSL, which belonged to cell protease, could be found to be enriched in cardiomyocytes. The results of enrichment analysis showed that differentially expressed genes (DEGs) in ACE2-positive cardiomyocytes were mainly enriched in the processes of cardiac muscle contraction, regulation of cardiac conduction, mitochondrial respiratory chain, ion channel binding, adrenergic signaling in cardiomyocytes and viral transcription. CONCLUSIONS: Our study suggests that both atrial and ventricular cardiomyocytes are potentially susceptible to severe acute respiratory syndrome coronavirus-2(SARS-CoV-2), and SARS-CoV-2 may enter ventricular cardiomyocytes using CTSB/CTSL for S protein priming. This may be the partial cellular mechanism of cardiac injury in patients with COVID-19.
format Online
Article
Text
id pubmed-7781406
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77814062021-01-05 Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes Yang, Jing Chen, Tan Zhou, Yafeng Hereditas Research BACKGROUND: The coronavirus disease 2019 (COVID-19) has spread rapidly around the world. In addition to common respiratory symptoms such as cough and fever, some patients also have cardiac injury, however, the mechanism of cardiac injury is not clear. In this study, we analyzed the RNA expression atlases of angiotensin-converting enzyme 2(ACE2), cathepsin B (CTSB) and cathepsin L (CTSL) in the human embryonic heart at single-cell resolution. RESULTS: The results showed that ACE2 was preferentially enriched in cardiomyocytes. Interestingly, serine protease transmembrane serine protease 2 (TMPRSS2) had less expression in cardiomyocytes, but CTSB and CTSL, which belonged to cell protease, could be found to be enriched in cardiomyocytes. The results of enrichment analysis showed that differentially expressed genes (DEGs) in ACE2-positive cardiomyocytes were mainly enriched in the processes of cardiac muscle contraction, regulation of cardiac conduction, mitochondrial respiratory chain, ion channel binding, adrenergic signaling in cardiomyocytes and viral transcription. CONCLUSIONS: Our study suggests that both atrial and ventricular cardiomyocytes are potentially susceptible to severe acute respiratory syndrome coronavirus-2(SARS-CoV-2), and SARS-CoV-2 may enter ventricular cardiomyocytes using CTSB/CTSL for S protein priming. This may be the partial cellular mechanism of cardiac injury in patients with COVID-19. BioMed Central 2021-01-04 /pmc/articles/PMC7781406/ /pubmed/33397514 http://dx.doi.org/10.1186/s41065-020-00168-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Jing
Chen, Tan
Zhou, Yafeng
Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title_full Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title_fullStr Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title_full_unstemmed Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title_short Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes
title_sort mediators of sars-cov-2 entry are preferentially enriched in cardiomyocytes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781406/
https://www.ncbi.nlm.nih.gov/pubmed/33397514
http://dx.doi.org/10.1186/s41065-020-00168-4
work_keys_str_mv AT yangjing mediatorsofsarscov2entryarepreferentiallyenrichedincardiomyocytes
AT chentan mediatorsofsarscov2entryarepreferentiallyenrichedincardiomyocytes
AT zhouyafeng mediatorsofsarscov2entryarepreferentiallyenrichedincardiomyocytes